PlainPharmaWatch

CMS Open Payments · Program Year 2024

Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. reported $12,749,404.11 in payments to 8,264 physicians and teaching hospitals across 10,143 transactions.

See the rankings → How this is sourced
$12.7M
Total payments
10,143
Transactions
8,264
Recipients
−$416.1K
General Payments vs PY2023

Apellis Pharmaceuticals, Inc. reported $12,749,404.11 in payments to 8,264 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #142 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $1.5K per recipient across 7 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Apellis Pharmaceuticals, Inc. pairs top-10% payment volume with a broadly spread payment pattern across many recipients.

#142
of 1,925 companies
0.1%
of all US industry payments
0.2%
paid to its single top recipient
7
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Apellis Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $416.1K (−10.6%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: APELLIS PHARMACEUTICALS, INC.PY2023: APELLIS PHARMACEUTICALS, INC.PY2024: Apellis Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$3.9MPY2024$3.5M
PY2023
$3,932,976.85
PY2024
$3,516,926.48

How Apellis Pharmaceuticals, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Apellis Pharmaceuticals, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$12,749,404 Top 7% higher than 93% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Apellis Pharmaceuticals, Inc.

$12,749,404.11: that is what Apellis Pharmaceuticals, Inc. reported in payments to 8,264 physicians and teaching hospitals during Program Year 2024, spread across 10,143 transactions ($1.3K per transaction, $1.5K per recipient). The company sits at rank #142 of 1,925, a comparatively small 0.1% slice of all industry payments reported nationwide for the year.

449 transactions worth $1.5M make "Compensation for Services Other Than Consulting" the top general-payment category in the 7-category breakdown below, 11.7% of the reported total (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Apellis Pharmaceuticals, Inc. made 7 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $1.5M, 11.7% of the company's reported total.

How Apellis Pharmaceuticals, Inc. divides its payments

How the reported total splits across payment categories

1. Compensation for Services…$1.5M2. Consulting Fee$1.3M3. Food and Beverage$311.4K4. Travel and Lodging$207.7K5. Honoraria$141.4K6. Space Rental or Facility …$40.5K7. Education$4.3K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $1.5M 449
Consulting Fee $1.3M 196
Food and Beverage $311.4K 6,917
Travel and Lodging $207.7K 469
Honoraria $141.4K 62
Space Rental or Facility Fees $40.5K 13
Education $4.3K 158

Recipient Concentration in General Payments

The five largest recipient relationships account for $1,147,353.02 (32.6%) of $3,516,926.48 in this company's General Payments records across 3,585 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Apellis Pharmaceuticals, Inc.

The five named recipients with the highest reported General Payments from this company

Denver Health Medical Center$758.1KEhsan Rahimy$121.7KDilsher Dhoot$97.3KJonathan Jonisch$97.2KAnkur Shah$73.1K
  1. 1

    Denver Health Medical Center

    $758,112.59 across 12 reported transactions

  2. 2

    Ehsan Rahimy

    $121,682.29 across 64 reported transactions

  3. 3

    Dilsher Dhoot

    $97,282.41 across 57 reported transactions

  4. 4

    Jonathan Jonisch

    $97,199.77 across 67 reported transactions

  5. 5

    Ankur Shah

    $73,075.96 across 45 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $1.3K. Average per recipient: $1.5K.

Total Amount

$12,749,404.11

Avg per Transaction

$1.3K

Avg per Recipient

$1.5K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Apellis Pharmaceuticals, Inc. Share

0.1%

#142 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Apellis Pharmaceuticals, Inc.

ShockWave Medical, Inc

$13.1M 21,799 recipients

Alcon Vision LLC

$13.4M 94,278 recipients

EMD Serono, Inc.

$12.1M 34,007 recipients

BeiGene USA, Inc.

$13.4M 11,760 recipients

Ultradent Products Inc

$13.4M 17,574 recipients

Blueprint Medicines Corporation

$13.5M 8,586 recipients

Frequently Asked Questions

How much did Apellis Pharmaceuticals, Inc. pay to physicians and hospitals in 2024? ▾
0.1% of all industry payments reported to CMS Open Payments for 2024 came from Apellis Pharmaceuticals, Inc., totaling $12,749,404.11 across 10,143 transactions to physicians and hospitals.
How many physicians received payments from Apellis Pharmaceuticals, Inc.? ▾
Apellis Pharmaceuticals, Inc. made payments to 8,264 physicians and teaching hospitals in 2024. The average payment per recipient was $1.5K.
What types of payments did Apellis Pharmaceuticals, Inc. make? ▾
General payments from Apellis Pharmaceuticals, Inc. span 7 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Compensation for Services Other Than Consulting" at $1.5M, representing 11.7% of the company's reported total.
How does Apellis Pharmaceuticals, Inc. rank among pharmaceutical companies? ▾
Out of 1,925 companies in the CMS Open Payments database for 2024, Apellis Pharmaceuticals, Inc. ranks #142 by total payment amount.
What is the average payment size from Apellis Pharmaceuticals, Inc.? ▾
The average transaction from Apellis Pharmaceuticals, Inc. was $1.3K in 2024. The company made 10,143 total transactions to 8,264 recipients.
Where does the payment data for Apellis Pharmaceuticals, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Apellis Pharmaceuticals, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.